If you want cheap medicine, Canadian taxpayers make it possible to get a great deal, but when it comes to new medicines, Canada is behind similar countries, according to a new report which ranks it 16th out of 18 comparable OECD countries.
Only 23% of 141 Health Canada-approved new medicines were included in public plans, ranking Canada 17 out of 18 there. Public drug plans in Canada make new medicines available only on a conditional, case-by-case basis, resulting in more administration, longer wait times for patients before beginning treatment, increased paperwork for physicians and no guarantee that patients will receive coverage.
The report further notes that:
In Canada, 29% of cancer medicines were covered in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, ranking Canada in 16th place of 18 countries.
Canadian public drug plans placed reimbursement conditions on 90% of new medicines when measured across provinces comprising 80% of the eligible national public drug plan population.
In Canada, 20% of new biologic medicines were reimbursed in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, putting Canada in 17th place of 18 countries.
